The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from CNW Group

iCo Therapeutics Ranked Number One in Technology & Life Sciences on 2013 TSX Venture 50

Thursday, February 14, 2013

iCo Therapeutics Ranked Number One in Technology & Life Sciences on 2013 TSX Venture 5015:03 EST Thursday, February 14, 2013VANCOUVER, Feb. 14, 2013 /CNW/ -iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) is pleased to announce it has been named the top ranked company in its class in the TSX Venture Top 50.The Venture 50 is the Exchange's annual list of the strongest performers from five industry sectors. iCo ranked number one among Technology & Life Science companies. Companies are selected based on four equally weighted criteria - return on investment, trading activity, market capitalization growth, and analyst coverage. The results were obtained from data to December 31, 2012."Our positive clinical update on our Phase 2 iDEAL study for the treatment of diabetic macular edema was well received by the sector and investment community, which has been demonstrated in our strong and growing performance in 2012," said Andrew Rae, President and CEO of iCo Therapeutics. "We expect to announce primary endpoint data from the iDEAL study before the end of the year and have several other catalyst events in 2013.  We aim to continue our 2012 momentum and hope to make the list again next year."As the top ranking Technology & Life Science company, iCo has been invited to attend the TSX Venture 50 Spotlight event in April, in Vancouver, with an opportunity to present to an audience comprised of portfolio managers, investment bankers, research analysts and investment advisors.About iCo TherapeuticsiCo Therapeutics in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The company has exclusive worldwide rights to two drug candidates - iCo-007 for Diabetic Macular Edema (DME) and iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2 clinical studies for DME. With Phase 2 clinical history, iCo-008 is targeted for the treatment of keratoconjunctivitis and wet age-related macular degeneration. In addition, iCo holds worldwide rights to an oral drug delivery platform. The first platform candidate is the Oral Amp B Delivery system, utilizing a known anti-fungal drug to treat life-threatening infectious diseases.  iCo trades on the TSX Venture Exchange under the symbol "ICO".  For more information, visit the Company website at: www.icotherapeutics.com.No regulatory authority has approved or disapproved the content of this release.  The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.    Forward Looking Statements Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo's current beliefs as well as assumptions made by and information currently available to iCo and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings; actual events may differ materially from current expectations. iCo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. SOURCE: iCo Therapeutics Inc.For further information: Mr. John Meekison, CFO iCo Therapeutics 604-602-9414 x 224 meekison@icotherapeutics.com  Michael Moore, Investor Relations TMX Equicom 619-467-7067 mmoore@tmxequicom.com